What is the main business of Abidopharma Pl?

The main business activity of Abidopharma Pl focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on January 20, 2006.

Where is the headquarters located?

The headquarters is located at: Popularna 62 A, 02-473 Warszawa.

Who is on the management board?

The management board consists of: Marek Ryszard Litmanowicz (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 50,000 (approx. $13,506).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What was the revenue?

In 2024, the company generated total revenue of USD 3,841, representing a decrease of 39.8% compared to 2023.

No, in 2024 the company was not profitable, reporting a net loss of USD 421.

What is the largest operating cost?

The largest operating cost category falls under external services. This category amounted to USD 3,692 in 2024, representing 100% of all operating expenses.

Abidopharma Plsp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Suspended

Registry date

2006-01-20

Share capital

50,000.00 PLN

Registered address

Popularna 62 A, 02-473 Warszawa, Poland

Financials

Revenue history

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 2 of 6 financial statements were filed late (the longest delay 53 days for 2021).

2025not filed
202405/07/2025
202313/07/2024
202218/07/2023
202106/09/2022
202007/07/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue

This companyUSD 3.84kMedianUSD 917.74kAverageUSD 25.73m

Net profit

This companyUSD -420.89MedianUSD 14.44kAverageUSD 2.75m

Operating costs

This companyUSD 3.69kMedianUSD 860.03kAverageUSD 21.34m

Assets

This companyUSD 4.16kMedianUSD 883.09kAverageUSD 31.39m

Industry

Trademarks

Abidopharma Pl currently holds no active trademarks with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2006.

Mark	Number	Classes	Status	Protected until
TAMERIT(word)	Z.312594	3, 5, 44	Expired	–
Mark without a word element(figurative)	Z.312592	44	Expired	–

Mark	Protected until
TAMERIT(word)	–
Mark without a word element(figurative)	–

Authorized Representatives

Marek Ryszard Litmanowicz – President of the Management Board

Manner of representation

In the case of a one-person management board, the company is represented by a member of the management board independently. In the case of a multi-member management board, the company is represented by two members of the management board acting jointly or by one member of the management board acting jointly with a commercial proxy.

Ownership

Owner	Shares	Share value	Stake
Musa Abidov	90	$12,155.59	90%
Marek Ryszard Litmanowiczage 72	10	$1,350.62	10%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2006-02-17.

ING Bank Śląski
65 1050 1054 1000 0023 0045 9209

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Xenira Pharmaceuticalssp. z o.o.	$26,670.82	xenirapharma.com
Sanford Biotechsp. z o.o.	$2,586.64	sanfordbiotech.com
IMP & Csp. z o.o.	$1,186.45	imp-c.pl

Change history

Date	Event
2026-10-08	PKD change (Removed: 11 codes)
2026-10-01	Business suspended
2009-08-31	Address change (Sportowa 1, 05-092, Łomianki → Popularna 62 A, 02-473, Warszawa)
2009-08-31	Switch to PKD 2007 (19 PKD 2004 codes → 21 PKD 2007 codes)
2006-01-20	Entered in the register

FAQ

Last updated: 2026-10-08